logo-loader
viewAIM ImmunoTech Inc.

Hemispherx Biopharma says FDA authorizes study using aspirin and flagship drug ampligen to treat prostate cancer

The Phase 2 study will be carried out at the Roswell Park Comprehensive Cancer Center in Buffalo and involve up to 60 patients

lab worker
Hemispherx also is studying ampligen to treat breast and ovarian cancers

Hemispherx Biopharma Inc. (NYSEAMERICAN:HEB) announced Monday that federal regulators will allow the company to proceed with a Phase 2 study of combining aspirin and its flagship drug ampligen to treat prostate cancer.

The study authorized by the US Food and Drug Administration will be carried out at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, involving up to 60 patients, the company said in a statement.

“This positive progress in commencing a new prostate cancer clinical trial is just one more step in our focused plan for R&D success," said CEO Thomas Equels.

READ: Hemispherx sees potential commercialization of flagship drug ampligen for Chronic Fatigue Syndrome

Hemispherx says the study will investigate the effectiveness and safety of aspirin and ampligen with or without drug interferon-alpha 2b (used to treat hepatitis and cancer) compared to no drug treatments in a randomized, three-arm study of patients with prostate cancer before they undergo radical prostatectomy.

The Orlando, Florida-based biotech said aspirin may help to keep the prostate cancer from recurring, while ampligen may stimulate the immune system and interfere with the ability of tumor cells to proliferate. Interferon-alpha 2b may improve the body’s natural response to infections and may slow tumor growth.

It is not yet known how well ampligen, aspirin, and interferon-alpha 2b will work in treating patients with prostate cancer undergoing surgery, the company added.

Hemispherx is studying ampligen to treat ovarian cancer and whether the drug is effective in treating breast cancer in combination with Merck’s (NYSE:MRK) cancer drug keytruda.

Equels said the amount of clinical trials showing progress with ampligen gives the company confidence that “now is the time for us to seek out big pharma partners who share our excitement and enthusiasm for the potential of ampligen.”

Hemispherx's stocks recently trade up 3% to $0.15 a share.

Contact the author: [email protected]vestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: AIM ImmunoTech Inc.

Price: 0.4052 USD

NYSE:AIM
Market: NYSE
Market Cap: $3.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019

2 min read